Application of cytogenetic endpoints and Comet assay on human lymphocytes treated with vincristine in vitro.
The genotoxic potential of vincristine is assessed on human peripheral blood lymphocytes following administration of the drug at a dose 0.0875 microg/ml by use of single cell gel electrophoresis - Comet assay (SCGE), analysis of structural chromosome aberrations (CA), micronucleus assay (MN) and sister chromatid exchange (SCE) analysis. In vitro treatment of human lymphocytes with vincristine was performed on cells in G0 phase, as well on lymphocyte cultures 24 hours after stimulation with mitogen phytohemagglutinine. For the Comet assay at 24, 48 and 72 h the treated cells were embedded in agarose on slides, lysed with alkaline lysis solution and exposed to an electric field. DNA migrated within the agarose and formed comets whose length depends on the amount of DNA damage. For the analysis of structural CA cells were grown on F-10 medium for 48 hours, and for MN and SCE analysis for 72 hours. The results on SCGE showed an increase in tail length compared to control both in cells treated in G0 and in cells treated 24 h after mitogen stimulation. The amount of DNA damage was higher in cells treated with vincristine 24 h after mitogen stimulation. Administered concentration of drug caused total inhibition of lymphocytes growth in 72-h cultures for MN and SCE analysis indicating strong microtubule distruptive effects of vincristine. Analysis of structural CA reveals chromatid breaks and acentric fragments as the main aberration types both in cells treated in G0 and in cells treated 24 h after mitogen stimulation. Number of these aberrations was higher in cells treated in G0 phase. Results obtained in this study by use of different cytogenetic endpoints confirmed that vincristine exhibits both aneugenic and clastogenic effects on human lymphocytes.
Kopjar
N
N
Institute for Medical Research and Occupational Health, Zagreb, Croatia. nkopjar@imi.hr
Garaj-Vrhovac
V
V
D000328:Adult; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology*; D002869:Chromosome Aberrations; D020552:Comet Assay; D020732:Cytogenetic Analysis; D005260:Female; D006801:Humans; D008214:Lymphocytes / Q000187:drug effects* / Q000502:physiology; D015162:Micronucleus Tests; D009152:Mutagenicity Tests; D012854:Sister Chromatid Exchange; D014750:Vincristine / Q000494:pharmacology*
D000972:Antineoplastic Agents, Phytogenic; D014750:Vincristine